Bezwoda W R, de Moor N G, Derman D, Lange M, Saner R, Dando R
Cancer. 1979 Aug;44(2):392-7. doi: 10.1002/1097-0142(197908)44:2<392::aid-cncr2820440204>3.0.co;2-d.
Two regimens of chemotherapy for metastatic breast cancer were compared in a randomized controlled fashion. Regimen 1 consisted of cyclophosphamide, vinblastine, methotrexate and 5-fluorouracil (CVMF). Regimen 2 consisted of cyclophosphamide, adriamycin, methotrexate and 5-fluorouracil (CAMF). The patient population consisted of both black and white postmenopausal females who had not received any prior chemotherapy. Objective responses were observed in 25/57 patients treated with CVMF and in 28/51 patients treated with CAMF. Neither race nor choice of chemotherapeutic regimen affected prognosis, although there were differences in the pattern of metastatic involvement between the two racial groups. The median duration of survival of patients who responded to therapy has not yet been reached but will be in excess of 12 months.
以随机对照的方式比较了两种转移性乳腺癌化疗方案。方案1由环磷酰胺、长春碱、甲氨蝶呤和5-氟尿嘧啶（CVMF）组成。方案2由环磷酰胺、阿霉素、甲氨蝶呤和5-氟尿嘧啶（CAMF）组成。患者群体包括未接受过任何先前化疗的绝经后黑人女性和白人女性。接受CVMF治疗的57例患者中有25例观察到客观缓解，接受CAMF治疗的51例患者中有28例观察到客观缓解。种族和化疗方案的选择均不影响预后，尽管两个种族群体之间的转移累及模式存在差异。对治疗有反应的患者的中位生存期尚未达到，但将超过12个月。
